VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Apellis Pharmaceuticals, Inc. (APLS) Total Return Calculator with Dividends Reinvested

Apellis Pharmaceuticals, Inc.

Popular:

The total return for Apellis Pharmaceuticals, Inc. (APLS) stock is +115.06% over the past 12 months. So far it's up 59.01% this year. The 5-year total return is -11.53%, meaning $10,000 invested in APLS stock 5 years ago would be worth $8,847 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in APLS 1 year ago, it would be worth $22,857 today — you'd have gained $12,857.

With Dividends Reinvested$22,857+128.57%

Price Only (No DRIP)$22,857+128.57%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in APLS

1Y$21,506+$11,506 (+115.1%)115.1% CAGR

3Y$4,500-$5,500 (-55.0%)-23.4% CAGR

5Y$8,847-$1,153 (-11.5%)-2.4% CAGR

10Y$29,309+$19,309 (+193.1%)11.4% CAGR

15Y$29,308+$19,308 (+193.1%)7.4% CAGR

20Y$29,308+$19,308 (+193.1%)5.5% CAGR

30Y$29,308+$19,308 (+193.1%)3.6% CAGR

Apellis Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading APLS total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+59.01%	—	+59.01%	—	$15,901
1Y	+115.06%	115.06%	+115.06%	—	$21,506
3Y	-55.00%	-23.37%	-55.00%	—	$4,500
5Y	-11.53%	-2.42%	-11.53%	—	$8,847
10Y	+193.09%	11.35%	+193.09%	—	$29,309
15Y	+193.08%	7.43%	+193.08%	—	$29,308
20Y	+193.08%	5.52%	+193.08%	—	$29,308
30Y	+193.08%	3.65%	+193.08%	—	$29,308

Risk & Highlights

Best Year+124.82%2019

Worst Year-47.92%2024

Max Drawdown-43.53%2025-10-29 → 2026-03-27 · Recovered 2026-03-31

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-18.95%	-18.95%	—	+0.41%	-19.4pp
2025	-24.25%	-24.25%	—	+16.64%	-40.9pp
2024	-47.92%	-47.92%	—	+24.00%	-71.9pp
2023	+19.05%	+19.05%	—	+24.81%	-5.8pp
2022	+6.03%	+6.03%	—	-19.95%	+26.0pp

APLS outperformed the S&P 500 by 83.74pp over the past year (+115.06% vs +31.32%).

Loading summary...

APLS Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
APLSApellis Pharmaceuticals, Inc.	$5.3B	+1.2%	+59.0%	+115.1%	—	-55.0%	-11.5%	+193.1%
RAREUltragenyx Pharmaceutical Inc.	$2.5B	+13.4%	+9.9%	-26.0%	—	-44.9%	-77.6%	-58.9%
BEAMBeam Therapeutics Inc.	$3.3B	+33.4%	+19.1%	+102.2%	—	-3.0%	-53.9%	+72.4%
AKROAkero Therapeutics, Inc.	$4.5B	—	—	+30.1%	—	+20.1%	+107.2%	+198.3%
INVAInnoviva, Inc.	$1.9B	-2.2%	+13.3%	+20.4%	—	+92.8%	+95.5%	+90.5%
BCABBioAtla, Inc.	$5M	-20.4%	-83.2%	-81.1%	—	-97.2%	-99.8%	-99.7%
REGNRegeneron Pharmaceuticals, Inc.	$74.9B	-5.5%	-7.0%	+29.7%	+0.6pp	-3.6%	+45.4%	+96.0%
BIIBBiogen Inc.	$28.2B	+10.6%	+7.2%	+63.2%	—	-39.3%	-29.9%	-27.7%
IONSIonis Pharmaceuticals, Inc.	$12.7B	+3.4%	-3.5%	+141.2%	—	+118.4%	+105.9%	+126.0%
OMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V.	$5.1B	-7.1%	-2.1%	+22.9%	+5.4pp	+39.7%	+157.3%	+189.2%
CHRSCoherus Oncology, Inc.	$212M	+4.8%	+27.7%	+88.2%	—	-78.5%	-87.9%	-90.9%

Compare:APLS vs RARE APLS vs BEAM APLS vs AKRO APLS vs RARE vs BEAM

About APLS Dividend Returns

Apellis Pharmaceuticals, Inc. (APLS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of APLS over the past year?

Apellis Pharmaceuticals, Inc. (APLS) delivered a return of 115.06% over the past year. Since APLS does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in APLS be worth today?

A $10,000 investment in Apellis Pharmaceuticals, Inc. one year ago would be worth $21,506 today, representing a gain of $11,506.

Q3Does APLS pay dividends?

Apellis Pharmaceuticals, Inc. (APLS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For APLS, the total return equals the price-only return.

Q4Did APLS beat the S&P 500?

Yes, Apellis Pharmaceuticals, Inc. (APLS) outperformed the S&P 500 by 83.74 percentage points over the past year. APLS delivered a total return of 115.06%, compared to the S&P 500's 31.32%. This 83.74pp alpha means investors in APLS earned more than a passive S&P 500 index fund.

Q5What is APLS's worst drawdown?

Apellis Pharmaceuticals, Inc. (APLS) experienced a maximum drawdown of -43.53% over the past year, declining from its peak on 2025-10-29 to its trough on 2026-03-27. The stock recovered to its prior peak by 2026-03-31. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is APLS's long-term total return over 10, 20, or 30 years?

Here are Apellis Pharmaceuticals, Inc. (APLS)'s long-term returns with dividends reinvested. Over 10 years, the total return is 193.1% (11.4% CAGR) — $10,000 would have grown to $29,309. Over 20 years: 193.1% total return (5.5% CAGR) — $10,000 → $29,308. Over 30 years: 193.1% total return (3.6% CAGR) — $10,000 → $29,308. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was APLS's best and worst year?

Apellis Pharmaceuticals, Inc.'s best calendar year was 2019 with a total return of 124.8%. Its worst year was 2024 with a total return of -47.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 172.7 percentage points.